Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, and Immunogenicity of VAL-339851 in Healthy Adult Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Agrees to comply with the study procedures and provides written informed consent~* 18 to 49 years of age~* Body mass index between 18 and 35 kg/m2~* Negative urine pregnancy test at the Screening visit and the day of each vaccination for females of childbearing potential.~* Female subjects must either be of non-childbearing potential or use acceptable methods of contraception from at least 3 weeks prior to enrollment and through the end of study visit~* In good health based on medical history, physical examination, vital sign measurements and laboratory safety tests performed prior to initial study vaccination~* Has access to a consistent and reliable means of telephone contact and agrees to stay in contact with the study site for the duration of the study~Exclusion Criteria:~* Any ongoing, symptomatic acute or chronic illness requiring medical or surgical care~* Administration of another investigational product within 60 days, or 5 half-lives, whichever is longer~* Participation in an investigational study involving lipid nanoparticles~* A history of hypersensitivity or serious reactions to previous influenza vaccinations~* History of Guillain-Barré Syndrome within 6 weeks following a previous influenza vaccine~* History of narcolepsy~* Administration of any licensed (inactivated or live) vaccines within 4 weeks before enrollment or plans to receive any vaccine within 12 weeks of the last study drug administration; receipt of any other avian H7N9 influenza vaccine at any time prior to or during the study is exclusionary~* Any known or suspected immunosuppressive condition, acquired or congenital, as determined by history and/or physical examination.~* Any chronic administration of immunosuppressant or other immune-modifying drugs within 6 months prior to administration of study vaccine~* Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study.~* Any acute disease at the time of enrollment~* Any significant disorder of coagulation requiring ongoing or intermittent treatment~* Active neoplastic disease or a history of any hematologic malignancy~* History of alcohol abuse or drug addiction within 1 year before the planned day of dose administration~* A positive test result for drugs of abuse or alcohol at screening or before the first dose administration~* Persons employed in a capacity that involves handling poultry or wild birds.~* The subject has any abnormality or permanent body art (eg, tattoo) that, in the opinion of the investigator, would obstruct the ability to observe local reactions at the injection site~* Any condition, that in the opinion of the Investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of the study results~* A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus types 1 or 2 antibodies at screening~* Donation of blood or blood products \> 450 mL within 30 days of dosing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- VAL-339851 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete